- Home
- FISI vs CMPX Comparison
FISI vs CMPX Comparison
Compare FISI & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FISI
- CMPX
- Stock Information
- Founded
- FISI 1817
- CMPX 2014
- Country
- FISI United States
- CMPX United States
- Employees
- FISI N/A
- CMPX N/A
- Industry
- FISI Major Banks
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- FISI Finance
- CMPX Health Care
- Exchange
- FISI Nasdaq
- CMPX Nasdaq
- Market Cap
- FISI 552.6M
- CMPX 576.5M
- IPO Year
- FISI 1999
- CMPX N/A
- Fundamental
- Price
- FISI $27.04
- CMPX $3.89
- Analyst Decision
- FISI Buy
- CMPX Strong Buy
- Analyst Count
- FISI 3
- CMPX 7
- Target Price
- FISI $33.00
- CMPX $14.71
- AVG Volume (30 Days)
- FISI 131.5K
- CMPX 1.8M
- Earning Date
- FISI 10-23-2025
- CMPX 11-11-2025
- Dividend Yield
- FISI 4.54%
- CMPX N/A
- EPS Growth
- FISI N/A
- CMPX N/A
- EPS
- FISI N/A
- CMPX N/A
- Revenue
- FISI $102,639,000.00
- CMPX N/A
- Revenue This Year
- FISI $82.14
- CMPX N/A
- Revenue Next Year
- FISI $6.97
- CMPX N/A
- P/E Ratio
- FISI N/A
- CMPX N/A
- Revenue Growth
- FISI N/A
- CMPX N/A
- 52 Week Low
- FISI $20.97
- CMPX $1.27
- 52 Week High
- FISI $29.79
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- FISI 57.37
- CMPX 54.31
- Support Level
- FISI $26.72
- CMPX $3.31
- Resistance Level
- FISI $27.53
- CMPX $3.80
- Average True Range (ATR)
- FISI 0.47
- CMPX 0.23
- MACD
- FISI 0.02
- CMPX -0.01
- Stochastic Oscillator
- FISI 66.90
- CMPX 56.05
About FISI Financial Institutions Inc.
Financial Institutions Inc operates as a financial holding company, engages in the provision of a wide range of consumer and commercial banking services to individuals, municipalities, and businesses in Western and Central New York. It operates through one segment: The Banking segment which includes all of the company's retail and commercial banking operations.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.